We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab in Lymphocyte-Predominant Hodgkin Disease.
- Authors
Azim Jr., Hatem A.; Pruneri, Giancarlo; Cocorocchio, Emilia; Cinieri, Saverio; Raviele, Paola R.; Bassi, Simona; Preda, Lorenzo; Martinelli, Giovanni; Peccatori, Fedro A.
- Abstract
Background: Lymphocyte-predominant Hodgkin disease (LPHD) differs in biology and clinical behaviour from classic Hodgkin disease. Almost 100% of LPHD neoplastic cells express CD20 and thus rituximab could be effective; yet limited data are available. Patients and Methods: We performed a retrospective analysis on patients with LPHD who were treated with rituximab at our institution to determine the magnitude of benefit offered by this drug. Results: Seven patients were identified; 4 received the drug as single agent while the rest received it in combination with chemotherapy. All except 2 received the drug in the salvage setting. Response rate was 100% with 6 of 7 patients achieving complete remission. At a median follow-up of 2 years, 4 patients are still disease free while the rest relapsed at a median time of 27 months. Conclusion: Rituximab is effective in LPHD and should be considered; however, the optimal schedule remains to be determined. Copyright © 2008 S. Karger AG, Basel
- Subjects
RITUXIMAB; ANTINEOPLASTIC agents; LYMPHOCYTES; LEUCOCYTES; HODGKIN'S disease
- Publication
Oncology, 2009, Vol 76, Issue 1, p26
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000177953